📊 ENOV Key Takeaways
Is Enovis CORP (ENOV) a Good Investment?
Enovis is unprofitable with deteriorating earnings (-39% EPS decline YoY) despite 6.7% revenue growth, indicating poor expense control and low-quality growth. Critical debt servicing risk emerges from an interest coverage ratio of 0.7x combined with negative free cash flow of -28.9M, while minimal cash of 33.1M relative to 1.3B long-term debt creates significant refinancing vulnerability.
Enovis shows respectable top-line growth and strong gross margins, but the fundamental picture is dominated by extreme operating and net losses, deeply negative returns on capital, and weak free cash flow conversion. Liquidity is adequate near term, but low cash balances, high leverage, and negative interest coverage materially weaken financial flexibility and make the current growth profile lower quality.
Enovis CORP Key Strengths (ENOV)
- Revenue growing 6.7% year-over-year in orthopedic appliances sector
- Strong gross margin of 62% demonstrates pricing power and manufacturing efficiency
- Current ratio of 2.04x indicates adequate short-term liquidity coverage
- Revenue grew 6.7% year over year, indicating continued demand growth
- Gross margin of 59.8% suggests a solid underlying product mix and pricing structure
- Current ratio of 2.02x and quick ratio of 1.04x indicate acceptable short-term liquidity
ENOV Stock Risks: Enovis CORP Investment Risks
- Operating margin of 1.1% is dangerously thin; company is unprofitable with -1.5% net margin
- Interest coverage ratio of 0.7x means operating income cannot service debt obligations
- Negative free cash flow of -28.9M is unsustainable; company is burning cash despite positive operations
- Only 33.1M cash against 1.3B long-term debt creates acute refinancing and covenant default risk
- EPS declining 39% year-over-year signals deteriorating profitability and shareholder value destruction
- Operating margin of -50.0% and net margin of -52.7% indicate severe profitability pressure
- Free cash flow was only $19.92M on $2.25B of revenue, showing weak cash conversion after capital spending
- Cash of $36.39M versus $1.30B of long-term debt and negative interest coverage creates balance sheet risk
Key Metrics to Watch
- Quarterly free cash flow trend and cash balance depletion rate
- Operating margin expansion and ability to reach breakeven profitability
- Debt covenant compliance and refinancing obligations in next 12-24 months
- Operating expense ratio reduction initiatives and restructuring progress
- Operating margin and net income trend
- Free cash flow generation relative to debt and interest burden
Enovis CORP (ENOV) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.04x current ratio provides a solid financial cushion.
ENOV Profit Margin, ROE & Profitability Analysis
ENOV vs Healthcare Sector: How Enovis CORP Compares
How Enovis CORP compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Enovis CORP Stock Overvalued? ENOV Valuation Analysis 2026
Based on fundamental analysis, Enovis CORP shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Enovis CORP Balance Sheet: ENOV Debt, Cash & Liquidity
ENOV Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Enovis CORP's revenue has declined by 42% over the 5-year period, indicating business contraction. The most recent EPS of $-0.61 indicates the company is currently unprofitable.
ENOV Revenue Growth, EPS Growth & YoY Performance
ENOV Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $558.8M | -$8.8M | $-0.15 |
| Q3 2025 | $505.2M | -$31.5M | $-0.58 |
| Q2 2025 | $525.2M | -$18.6M | $-0.34 |
| Q1 2025 | $516.3M | -$56.0M | $-0.98 |
| Q3 2024 | $417.5M | -$2.9M | $-0.05 |
| Q2 2024 | $428.5M | -$10.0M | $-0.18 |
| Q1 2024 | $406.2M | -$23.4M | $-0.43 |
| Q3 2023 | $383.8M | -$2.9M | $-0.05 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Enovis CORP Dividends, Buybacks & Capital Allocation
ENOV SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Enovis CORP (CIK: 0001420800)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ENOV
What is the AI rating for ENOV?
Enovis CORP (ENOV) has a Combined AI Grade of C from Claude (D) and ChatGPT (C) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ENOV's key strengths?
Claude: Revenue growing 6.7% year-over-year in orthopedic appliances sector. Strong gross margin of 62% demonstrates pricing power and manufacturing efficiency. ChatGPT: Revenue grew 6.7% year over year, indicating continued demand growth. Gross margin of 59.8% suggests a solid underlying product mix and pricing structure.
What are the risks of investing in ENOV?
Claude: Operating margin of 1.1% is dangerously thin; company is unprofitable with -1.5% net margin. Interest coverage ratio of 0.7x means operating income cannot service debt obligations. ChatGPT: Operating margin of -50.0% and net margin of -52.7% indicate severe profitability pressure. Free cash flow was only $19.92M on $2.25B of revenue, showing weak cash conversion after capital spending.
What is ENOV's revenue and growth?
Enovis CORP reported revenue of $589.2M.
Does ENOV pay dividends?
Enovis CORP pays dividends, with $5.1M distributed to shareholders in the trailing twelve months.
Where can I find ENOV SEC filings?
Official SEC filings for Enovis CORP (CIK: 0001420800) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ENOV's EPS?
Enovis CORP has a diluted EPS of $-0.15.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ENOV's fundamental grade?
Based on our AI fundamental analysis in June 2026, Enovis CORP has a C grade with 88% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ENOV stock overvalued or undervalued?
Valuation metrics for ENOV: ROE of -0.6% (sector avg: 15%), net margin of -1.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ENOV's AI grade for 2026?
Our dual AI analysis gives Enovis CORP a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ENOV's free cash flow?
Enovis CORP's operating cash flow is $24.0M, with capital expenditures of $52.8M. FCF margin is -4.9%.
How does ENOV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1.5% (avg: 12%), ROE -0.6% (avg: 15%), current ratio 2.04 (avg: 2).